Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.10 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including brain inhibitory neurons; strongest in thyrotrophs | 0.75 |
| chemistry Open Targets | compounds already reach it: azd1305, isradipine, cinnarizine +38 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 369 | 0.76 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2594
Sealed predictions
- CACNA1D in dopamine neurons, braak+0.11 (p 0.778) → -0.39 (p 0.297)receipt 2601
Swarm cases
receipt 2601: CACNA1D in dopamine neurons, braak
- power
- full sample -0.20 (p 0.418, n 18), 95% CI -0.61 to +0.29. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.16 (p 0.526, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.35 (p 0.153, n 18). could be the mix.
- skeptic
- leave-one-out range -0.33 to -0.10, sign flips 0; without severely affected donors -0.20 (p 0.418, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CACNA1D in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts